BioTools Innovator 2025 Cohort Includes Top 31 Life Sciences Tools and Diagnostics Companies

LOS ANGELES--(BUSINESS WIRE)--BioTools Innovator (BTI), the first accelerator focused exclusively on life science tools and diagnostics startups, has selected 31 companies for its 2025 Accelerator program. These startups will participate in a four-month program offering in-depth, personalized mentorship from senior industry leaders, access to funding opportunities, and meaningful engagement with peers and expert advisors. Chosen from a highly competitive pool of more than 400 applicants, the selected companies represent the top 7% of applicants. At the end of the program, participants will compete for $300,000 in cash prizes.

“BioTools Innovator was created to bridge critical gaps for life science entrepreneurs, providing industry-specific mentorship, resources, and connections they need to successfully commercialize their technologies,” said Kathryn Zavala, managing director of BioTools Innovator. “Now in our fifth year, we’re proud to support a growing network of innovators who are advancing tools and diagnostics that have the potential to transform research, medicine, and human health. We’re excited to welcome this outstanding 2025 cohort.”

The 31 companies awarded a spot in the BioTools Innovator 2025 Accelerator are:

• Advemto - Wellington, New Zealand
• Amplified Sciences - West Lafayette, Ind.
• Amptiv Biosciences - Cleveland
• ArgenTag - New York
• Aridica* - Boulder, Colo.
• Avenue Biosciences - Palo Alto, Calif.
• Brightest Bio* - Overland, Mo.
• ChemT Biotechnology - Singapore
• CHO Plus* - San Francisco
• Diagnostic Biochips - Glen Burnie, Md.
• EMPIRI - Houston
• Encapsulate - Farmington, Conn.
• Eukarys* - Paris
• Evoworks Bio* - Cambridge, Mass.
• ExoDiscovery - Austin, Texas
• Flow.bio - London
• Full Circles Therapeutics - Cambridge, Mass.
• InnovaPrep - Drexel, Mo.
• Inso Biosciences* - Ithaca, N.Y.
• IRUBIS - Munich
• Likarda - Kansas City, Mo.
• Model Medicines* - San Diego
• Nanovery - Newcastle upon Tyne, United Kingdom
• Nirrin Technologies - Billerica, Mass.
• Novilytic - West Lafayette, Ind.
• Osem Fluidics* - Alhambra, Calif.
• Oxbridge Clinical* - Boston
• Precision Chroma - Christchurch, New Zealand
• Ramona Optics* - Durham, N.C.
• TissueLabs - Bellinzona, Switzerland
• VisiCELL Medical - San Diego

*VANGUARD Cohort Company

Ten companies from this year’s cohort have also been selected to participate in the VANGUARD Accelerator track. VANGUARD is a joint initiative between BioTools Innovator and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support startups in deploying innovative medical countermeasures that enhance the U.S.’ readiness for public health emergencies.**

The BioTools Innovator 2025 cohort will attend the program’s kick-off at the Innovator Summit 2025, held June 24-26 in Mountain View, Calif. There, they’ll join the MedTech Innovator (MTI) U.S. and Asia Pacific cohorts in a closed-door event that brings together the programs’ corporate partners, alumni, and other industry leaders.

As part of a rigorous evaluation process, BioTools Innovator and its corporate partners invited 83 companies to pitch at this year’s BioTools Innovator Road Tour events in Boston, San Diego, as well as its inaugural international event hosted by Miltenyi Biotec in Bergisch Gladbach, Germany. The final cohort was selected by the BioTools Innovator selection committee, which included the senior leadership teams of the program’s corporate partners: Research Corporation Technologies (RCT), BroadOak Capital Partners, Nissan Chemical America Corporation, and Thermo Fisher Scientific, with input from more than 240 industry judges from leading life science firms.

The mentors, judges, and advisors in this year’s BioTools Innovator’s expert ecosystem include representatives from AbbVie, Agilent, Catalent Pharma Solutions, Danaher, Draper, Eppendorf, GenScript, Genentech, Illumina, Lonza Biopharma, M Ventures, New England Biolabs, Novartis, Novo Nordisk, Quanterix, Qiagen, Sartorius, and Standard BioTools, among others. Funding for BioTools Innovator is provided by the Frederick Gardner Cottrell Foundation of RCT. Additional support is provided by BroadOak Capital Partners, Nissan Chemical America Corporation, and Thermo Fisher Scientific.

**This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under agreement number 75A50124C00034.

About BioTools Innovator

Based in Los Angeles, BioTools Innovator was established to advance cutting-edge research and improve human health by accelerating the growth of a broad spectrum of life science tools and diagnostics. BioTools Innovator matches industry leaders with innovative early-stage and emerging growth biotechnology-focused companies for mentorship and support.

BioTools Innovator is powered by MedTech Innovator (MTI), the world’s largest accelerator of medical technology companies and the premier nonprofit startup accelerator in the medical technology industry. To date, MTI alumni have collectively brought over 400 products to market and raised $10 billion in follow-on funding. For more information about BioTools Innovator, visit the website and follow the organization on LinkedIn.